Paper42136641
Modulating CD38 enzymatic activity during antibody-based immunotherapy in multiple myeloma: a basic science perspective.
Horenstein AL and 4 others. Front Immunol, 2026. Cited by 4 papers, by iCite.
Cite this record
ConductScience Library. Modulating CD38 enzymatic activity during antibody-based immunotherapy in multiple myeloma: a basic science perspective. Papers, record 42136641. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42136641
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Modulating CD38 enzymatic activity during antibody-based immunotherapy in multiple myeloma: a basic science perspective.
- PubMed
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Multiple Myeloma | Major topic |
| ADP-ribosyl Cyclase 1 | Major topic |
| Antibodies, Monoclonal | Major topic |
| Immunotherapy | Major topic |
| Membrane Glycoproteins | Major topic |
| Antineoplastic Agents, Immunological | Major topic |
| Humans | |
| Adenosine | |
| NAD | |
| Cell Line, Tumor | |
| Inosine | |
| Animals | |
| GPI-Linked Proteins | |
| Antibodies, Monoclonal, Humanized |
Source PubMed
References105
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 22969159 | The membrane-bound enzyme CD38 exists in two opposing orientations. | Sci Signal | 2012 | https://conductscience.org/library/papers/22969159 | PubMed |
| 2 | 37418547 | The interplay between the DNA damage response and ectonucleotidases modulates tumor response to therapy. | Sci Immunol | 2023 | https://conductscience.org/library/papers/37418547 | PubMed |
| 3 | 29719225 | A Potent and Specific CD38 Inhibitor Ameliorates Age-Related Metabolic Dysfunction by Reversing Tissue NAD+ Decline. | Cell Metab | 2018 | https://conductscience.org/library/papers/29719225 | PubMed |
| 4 | 27316683 | The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor-Mediated Cross-Linking. | J Immunol | 2016 | https://conductscience.org/library/papers/27316683 | PubMed |
| 5 | 27307294 | CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma. | Blood | 2016 | https://conductscience.org/library/papers/27307294 | PubMed |
| 6 | 26903141 | The adenosine metabolite inosine is a functional agonist of the adenosine A2A receptor with a unique signaling bias. | Cell Signal | 2016 | https://conductscience.org/library/papers/26903141 | PubMed |
| 7 | 31350295 | The Tumor Microenvironment Innately Modulates Cancer Progression. | Cancer Res | 2019 | https://conductscience.org/library/papers/31350295 | PubMed |
| 8 | 40632830 | Potential functions of TRPM2 and TRPM7 channels in the tumor microenvironment. | J Leukoc Biol | 2025 | https://conductscience.org/library/papers/40632830 | PubMed |
| 9 | 39364393 | Targeting CD38 with monoclonal antibodies disrupts key survival pathways in paediatric Burkitt's lymphoma malignant B cells. | Clin Transl Immunology | 2024 | https://conductscience.org/library/papers/39364393 | PubMed |
| 10 | 34625791 | Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma. | Blood Adv | 2021 | https://conductscience.org/library/papers/34625791 | PubMed |
| 11 | 39985195 | Targeting the Adenosine-Mediated Metabolic Immune Checkpoint with Engineered Probiotic for Enhanced Chemo-Immunotherapy. | Adv Sci (Weinh) | 2025 | https://conductscience.org/library/papers/39985195 | PubMed |
| 12 | 9748331 | The reaction mechanism for CD38. A single intermediate is responsible for cyclization, hydrolysis, and base-exchange chemistries. | Biochemistry | 1998 | https://conductscience.org/library/papers/9748331 | PubMed |
| 13 | 32844992 | The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications. | Blood | 2020 | https://conductscience.org/library/papers/32844992 | PubMed |
| 14 | 21187443 | Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. | J Immunol | 2011 | https://conductscience.org/library/papers/21187443 | PubMed |
| 15 | 30359421 | Accurate measurement of endogenous adenosine in human blood. | PLoS One | 2018 | https://conductscience.org/library/papers/30359421 | PubMed |
| 16 | 28373875 | Roles and Modalities of Ectonucleotidases in Remodeling the Multiple Myeloma Niche. | Front Immunol | 2017 | https://conductscience.org/library/papers/28373875 | PubMed |
| 17 | 32049008 | Prebiotic-Induced Anti-tumor Immunity Attenuates Tumor Growth. | Cell Rep | 2020 | https://conductscience.org/library/papers/32049008 | PubMed |
| 18 | 38464531 | Different evasion strategies in multiple myeloma. | Front Immunol | 2024 | https://conductscience.org/library/papers/38464531 | PubMed |
| 19 | 33096610 | The Circular Life of Human CD38: From Basic Science to Clinics and Back. | Molecules | 2020 | https://conductscience.org/library/papers/33096610 | PubMed |
| 20 | 23420183 | Multiple myeloma-initiating cells. | Int J Hematol | 2013 | https://conductscience.org/library/papers/23420183 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42724012 | Effect of daratumumab on patients with high-risk cytogenetic multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. | Front Immunol | 2026 | https://conductscience.org/library/papers/42724012 | PubMed |
| 42709393 | Beyond a Surface Marker: The Multifaceted Role of CD38 in Metabolic Disruption and Tumor Progression. | Cell Biochem Biophys | 2026 | https://conductscience.org/library/papers/42709393 | PubMed |
| 42608642 | Targeting CD38 Across Autoimmune and Plasma Cell-Driven Immune-Mediated Diseases: Rationale, Clinical Evidence, and Emerging Therapeutic Landscape. | BioDrugs | 2026 | https://conductscience.org/library/papers/42608642 | PubMed |
| 42587741 | Mechanistic and Clinical Differences Between Daratumumab and Isatuximab in Multiple Myeloma: Emerging Roles of 1q Gain and Immune Remodeling. | Cells | 2026 | https://conductscience.org/library/papers/42587741 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ADA | 100 | PubTator's text mining | https://conductscience.org/library/genes/100 | NCBI Gene |
| CD38 | 952 | PubTator's text mining | https://conductscience.org/library/genes/952 | NCBI Gene |
| NT5E | 4907 | PubTator's text mining | https://conductscience.org/library/genes/4907 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42136641
GET https://conductscience.org/api/papers/v1/42136641/references?page=2